Compared side by side
Cagrilintide vs petrelintide: how they differ
The short answer
Both are long-acting, weekly copies of amylin, the fullness hormone the pancreas releases with insulin: cagrilintide, Novo Nordisk’s, lasts about a week, and petrelintide, from Zealand Pharma and Roche, lasts about 10 days and was designed to stay stable at neutral pH so it can be mixed with other peptides. Neither is approved: cagrilintide is the amylin half of CagriSema, and petrelintide has been in phase 3 since September 2026. On their own, cagrilintide’s higher doses led to about 10–12% weight loss in trials, and petrelintide’s up to about 10.7% by week 42, with GI side effects close to placebo apart from mild nausea.
Side by side
| Compared | Cagrilintide | Petrelintide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Cagri, AM833, NNC0174-0833 | ZP8396, Petre |
| What it is | A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. | A once-weekly amylin drug from Zealand Pharma and Roche, a long-acting copy of the fullness hormone the pancreas releases with insulin. |
| How it works | Long-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema. | Long-acting analogue of human amylin, the fullness hormone the pancreas releases with insulin. Amylin receptor activation is thought to make the body more responsive to leptin, its satiety signal, so people feel full sooner. A fatty-acid chain binds it to albumin in the blood, giving a half-life of about 10 days. Zealand designed it to stay stable at neutral pH so it can be mixed with other peptides, and Roche is testing it with its own GLP-1 drug. Investigational, in phase 3 since September 2026. |
| Commonly reported | Feeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own. | Feeling full sooner and smaller portions. It is in phase 3 and not approved anywhere. |
| Studied range | Research range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation. | Research range: 1–9 mg, starting dose 0.6 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~1 week (measured in people: 159–195 hours in a phase 1b trial) | ~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | Trials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1. | Used continuously, once weekly, in its trials: 42 weeks in ZUPREME-1 and 28 weeks in ZUPREME-2, with steps every 4 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, constipation, diarrhea, injection-site reactions | Nausea, decreased appetite, constipation, diarrhea |
- Category
- CagrilintideMetabolic & GLP-1
- PetrelintideMetabolic & GLP-1
- Also known as
- CagrilintideCagri, AM833, NNC0174-0833
- PetrelintideZP8396, Petre
- What it is
- CagrilintideA long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot.
- PetrelintideA once-weekly amylin drug from Zealand Pharma and Roche, a long-acting copy of the fullness hormone the pancreas releases with insulin.
- How it works
- CagrilintideLong-acting, lipidated analogue of amylin, the satiety hormone the pancreas releases with insulin. It activates amylin receptors and the calcitonin receptor (a non-selective amylin agonist); amylin promotes fullness, slows stomach emptying and holds back glucagon after meals. A fatty-acid chain stretches its half-life to about a week, so it is a weekly shot, usually run beside a GLP-1. Not approved on its own: it is the amylin half of Novo Nordisk's CagriSema.
- PetrelintideLong-acting analogue of human amylin, the fullness hormone the pancreas releases with insulin. Amylin receptor activation is thought to make the body more responsive to leptin, its satiety signal, so people feel full sooner. A fatty-acid chain binds it to albumin in the blood, giving a half-life of about 10 days. Zealand designed it to stay stable at neutral pH so it can be mixed with other peptides, and Roche is testing it with its own GLP-1 drug. Investigational, in phase 3 since September 2026.
- Commonly reported
- CagrilintideFeeling full sooner and portions shrinking, with nausea or constipation after step-ups and some injection-site reactions. It is not approved on its own.
- PetrelintideFeeling full sooner and smaller portions. It is in phase 3 and not approved anywhere.
- Studied range
- CagrilintideResearch range: 0.25–2.4 mg, starting dose 0.25 mg. Studied in research — not a recommendation.
- PetrelintideResearch range: 1–9 mg, starting dose 0.6 mg. Studied in research — not a recommendation.
- How often
- CagrilintideWeekly
- PetrelintideWeekly
- Half-life
- Cagrilintide~1 week (measured in people: 159–195 hours in a phase 1b trial)
- Petrelintide~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026)
- Route
- CagrilintideSubQ injection
- PetrelintideSubQ injection
- Typical run
- CagrilintideTrials run it continuously: 26 weeks in phase 2, 68 weeks in phase 3. Community use is mostly as a weekly add-on to a GLP-1.
- PetrelintideUsed continuously, once weekly, in its trials: 42 weeks in ZUPREME-1 and 28 weeks in ZUPREME-2, with steps every 4 weeks. No trial has tested stopping it.
- Evidence
- CagrilintideEstablished: clinical trials or FDA-approved use exists
- PetrelintideModerate: animal studies + some human data
- Common side effects
- CagrilintideNausea, constipation, diarrhea, injection-site reactions
- PetrelintideNausea, decreased appetite, constipation, diarrhea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Cagrilintide
- Day 1–28 · 0.25 mg The 0.25 mg start
- Day 29–364 · 0.5 mg 0.5 mg, the second step
- Day 57–364 · 1 mg 1 mg, the middle step
- Day 85–364 · 1.7 mg 1.7 mg, the step before 2.4 mg
- Day 113+ · 2.4 mg 2.4 mg, the phase 3 dose
Petrelintide
- Day 1–28 Fullness, gently
- Day 29–294 · 2.5 mg Low doses already work
- Day 57–294 · 5 mg Five milligrams
- Day 85–294 · 9 mg The top dose tested
- Day 85–294 With type 2 diabetes
- Day 197–294 Weeks 28 to 42: still moving
Questions people ask
How long do cagrilintide and petrelintide last?
The half-life of cagrilintide is ~1 week (measured in people: 159–195 hours in a phase 1b trial). The half-life of petrelintide is ~10 days (measured in people: mean 213–257 h after SubQ doses, 239 h IV; Brændholt Olsen 2026).
How often are cagrilintide and petrelintide taken?
Cagrilintide: weekly. Route: SubQ injection. Petrelintide: weekly. Route: SubQ injection.
How are cagrilintide and petrelintide dosed in research?
The research range for cagrilintide is 0.25–2.4 mg, with a 0.25 mg starting dose. The research range for petrelintide is 1–9 mg, with a 0.6 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of cagrilintide and petrelintide?
For cagrilintide, the library lists: nausea, constipation, diarrhea, injection-site reactions. For petrelintide: nausea, decreased appetite, constipation, diarrhea.